These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26412063)

  • 21. [Effect of neurotransmitters and psychotropic drugs on the immune system. Mediator role of hormones and clinical implications].
    Martin-Du Pan RC; Dayer JM
    Schweiz Med Wochenschr; 1982 Dec; 112(52):1910-20. PubMed ID: 6131535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia.
    Vita A; De Peri L
    Int Rev Psychiatry; 2007 Aug; 19(4):429-36. PubMed ID: 17671875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development.
    Möller M; Swanepoel T; Harvey BH
    ACS Chem Neurosci; 2015 Jul; 6(7):987-1016. PubMed ID: 25794269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antipsychotic drugs and drugs inducing psychoses].
    Deniker P
    Acta Psychiatr Belg; 1983; 83(3):239-54. PubMed ID: 6138922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.
    Kim YK; Choi J; Park SC
    Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28358303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principles of French pharmaco-clinical classification.
    Deniker P
    Prog Neuropsychopharmacol; 1980; 4(4-5):455-68. PubMed ID: 6111816
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel treatments of schizophrenia: targeting the neurotensin system.
    Kinkead B; Nemeroff CB
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.
    Lieberman JA; Perkins D; Belger A; Chakos M; Jarskog F; Boteva K; Gilmore J
    Biol Psychiatry; 2001 Dec; 50(11):884-97. PubMed ID: 11743943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders.
    Ban TA
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):527-80. PubMed ID: 2892227
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review.
    Smieskova R; Fusar-Poli P; Allen P; Bendfeldt K; Stieglitz RD; Drewe J; Radue EW; McGuire PK; Riecher-Rössler A; Borgwardt SJ
    Curr Pharm Des; 2009; 15(22):2535-49. PubMed ID: 19689326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic implications of hemispheric asymmetry.
    Myslobodsky M; Weiner M
    Life Sci; 1976 Nov; 19(10):1467-78. PubMed ID: 11380
    [No Abstract]   [Full Text] [Related]  

  • 33. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 34. [Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia].
    Cassan P
    Ann Med Psychol (Paris); 1985 Jul; 143(7):677-82. PubMed ID: 2870674
    [No Abstract]   [Full Text] [Related]  

  • 35. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.
    Dean B; Scarr E
    Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):217-25. PubMed ID: 15180482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychopharmacology: much the same.
    Grgas M; Ehret MJ
    Conn Med; 2009 May; 73(5):281-4. PubMed ID: 19441763
    [No Abstract]   [Full Text] [Related]  

  • 37. The development of new drugs for the treatment of schizophrenia.
    Cookson J
    Br J Hosp Med; 1987 Dec; 38(6):542-8. PubMed ID: 2893648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium signaling dysfunction in schizophrenia: a unifying approach.
    Lidow MS
    Brain Res Brain Res Rev; 2003 Sep; 43(1):70-84. PubMed ID: 14499463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromodulatory mechanism underlying the effect of the atypical dipeptide neuroleptic dilept.
    Retyunskaya MV; Guzevatykh LS; Bondarenko NA; Gudasheva TA; Ostrovskaya RU; Voronina TA
    Bull Exp Biol Med; 2003 Nov; 136(5):467-70. PubMed ID: 14968162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.